The Peptide Receptor Radionuclide Therapy (PRRT) Industry is on a trajectory of exceptional growth, with projections indicating a worth of US$ 591.83 million in 2023 and a substantial leap towards US$ ...

Neuroendocrine cancer is exceedingly difficult to manage and unlikely to be cured, but researchers intend to slow progression of these tumors and aid survival by personalizing patient dose of ...

The Global Peptide Receptor Radionuclide Therapy (PRRT) Industry is on the cusp of substantial growth, with a projected value of US$ 591.83 million in 2023. According to the latest market analysis, ...

The researchers suggest that PRRT should more readily be considered a first-line agent in appropriate patients. Steps can be taken to minimize the risk of significant long-term effects, such as ...

Peptide receptor radionuclide therapy (PRRT) with lutetium dotatate is a treatment for well-differentiated neuroendocrine tumors that the U.S. Food and Drug Administration approved in 2018, but ...

A simple blood draw can provide physicians with valuable information that can determine if peptide receptor radionuclide therapy (PRRT) is likely to be effective in a patient with neuroendocrine ...

Since its approval in 2018 by the US Food and Drug Administration, peptide receptor radionuclide therapy (PRRT) has become a mainstay in the treatment of neuroendocrine tumors. Lutetium-177-DOTATATE, ...

A 12-year retrospective clinical study of patients who received peptide receptor radionuclide therapy (PRRT) for malignant neuroendocrine tumors demonstrates the long-term effectiveness of this ...

Patients with neuroendocrine tumours are increasingly treated with peptide receptor radionuclide therapy. However, tumour somatostatin receptor expression evaluation cannot accurately predict who will ...

Patients with neuroendocrine tumors (NETs) may experience fewer symptoms and survive longer by undergoing peptide-receptor radionuclide therapy (PRRT) combined with a drug that makes tumor cells more ...

Transaxial slices of baseline positron emission tomography (PET) and fused PET/magnetic resonance imaging (MRI; left) demonstrate a somatostatin receptor-expressing meningioma in the left cavernous ...